Market research
CTXR Citius Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US17322U3068
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 0.99
About
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CTXR discussion.
5 years, 4 months ago
Citius Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 28.0% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Citius Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 88.5% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 87.0% to $-10M since the same quarter in the previous year.
Based on the above factors, Citius Pharmaceuticals, Inc gets an overall score of 2/5.